BioStock interview with Åsa Schiött, Chief Scientific Officer at Idogen

Åsa Schiött has headed Idogen’s research and development department in the role of Chief Scientific Officer since September 2020.

In an interview with BioStock, Åsa Schiött talks about her background, her first six months at Idogen and the exciting phase of preparing the company's tolerogenic cell therapy for the first clinical trial in patients with severe hemophilia A.

Read the interview here

For further information, please contact:
Anders Karlsson, CEO Idogen AB
Phone: +46 (0) 709 18 00 10
Email:  anders.karlsson@idogen.com

Certified Adviser
The company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm; phone: +46 (0) 8-463 80 00, email: certifiedadviser@penser.se.

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralising antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient’s own cells and is expected to have a favourable safety profile and long-lasting effect. The potential for a short-term treatment to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.

Tags: